DOI:

A rare publication with a unique message: the joint guidelines on the management of valvular heart disease by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery

Davide Capodanno

This February issue is special because it contains only one article, but what an article! In fact, we are co-publishing the guidelines of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery on the management of valvular heart disease. We also have a timely editorial by Catherine Otto, first author of the joint American College of Cardiology and American Heart Association guidelines on the same topic, which illustrates the main similarities and differences of the two documents that come from either side of the Atlantic. On this occasion, I would like to thank the European Society of Cardiology for allowing the co-publication of this document in our Journal and the European Association of Percutaneous Cardiovascular Interventions, with its Board and Presidential trio, for their support in carrying out this request. I was part of the Task Force that drafted these guidelines, so I will refrain from personal comments on the contents. Social media, as always, has amplified the discussion around guidelines presented at the European Society of Cardiology Congress – which is positive for their broad dissemination and uptake. I have a feeling that the key principles of this document have been well-received, without divisions that go beyond the normal and fair scientific debate. After all, these are guidelines produced by the European Society of Cardiology together with the European Association for Cardio-Thoracic Surgery, which represents the most exemplary illustration of the Heart Team concept that is interwoven transversally throughout the document. Unsurprisingly, and in general, the guidelines methodology is debated. Catherine Otto, in her Editorial, mentions some aspects that can be improved upon with a view to creating an ever-better process. What I have learned as an author, however, is that the process is more solid than what I, myself, could have expected as a reader (and of course, you can decide to trust me or not). The process is intended to foster debate, representing different opinions and the involvement not only of the multidisciplinary components of the task force, but of countless reviewers as well. Contrary to more conspiratorial views, from what I can testify from my own personal experience, this is not a process that allows overly extreme or potentially biased opinions to take the lead. A methodological review is undertaken and strict rounds of votes with prespecified criteria are required before the several rounds of review process begin. I have seen some who are reluctant to reconcile their positions converge after long discussions in the interest of science and community service. I have no counterevidence to support this, but I would like to think that different people, using the same methodology and moving from the same extremes, would reach the same recommendations. That said, guidelines exist to inform readers about best practices regarding the treatment of certain conditions. It is up to us to read and interpret them for what they are: a practical guide that does not replace decisions based on science, experience and conscience, all in the best interests of our patients.

Supplementary data

To read the full content of this article, please download the PDF.

Volume 17 Number 14
Feb 4, 2022
Volume 17 Number 14
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00479 Jun 1, 2026
Valve thrombosis or valve deterioration: what truly drives the prognosis?
Waksman R and Phichaphop A
free

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free

Original Research

10.4244/EIJ-D-25-01370 Jun 1, 2026
Prognostic value of early haemodynamic valve deterioration after TAVI
Trimaille A et al

Original Research

10.4244/EIJ-D-25-01268 Jun 1, 2026
Early outcomes of redo-TAVI with the SAPIEN 3 platform: the prospective, multicentre ReTAVI registry
Tarantini G et al

Research Correspondence

10.4244/EIJ-D-25-01160 Jun 1, 2026
First-in-human experience with a heterotopic cross-caval transcatheter tricuspid valve replacement
Estevez-Loureiro R et al

Original Research

10.4244/EIJ-D-26-00416 May 21, 2026
Long-term clinical outcomes of high-risk plaques with negative fractional flow reserve: the PECTUS-obs study
Volleberg R et al
Trending articles
87.2

State-of-the-Art

10.4244/EIJ-D-25-00266 Jan 19, 2026
Lesion stratification with intracoronary imaging
McGarvey M et al
free
47.45

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
34.8

Original Research

10.4244/EIJ-D-25-01006 Mar 16, 2026
Clinical outcomes and haemodynamic response after blinded stress assessment of moderate aortic stenosis
Eerdekens R et al
22.2

Viewpoint

10.4244/EIJ-D-25-01066 May 4, 2026
Intracoronary imaging guidance for de novo coronary lesion treatment with drug-coated balloons
Amabile N et al
free
20.75

Flashlight

10.4244/EIJ-D-25-01014 Apr 6, 2026
Stent retriever-assisted coronary thrombectomy with continuous aspiration
Liabot Q et al
open access
19.5

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
17.8

Expert Review

10.4244/EIJ-D-25-01316 Apr 20, 2026
Electrosurgical laceration and stabilisation of tricuspid edge-to-edge repair: the ELASTA-T technique
Alvarez-Covarrubias H et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved